Vor Biopharma (NASDAQ:VOR) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Vor Biopharma (NASDAQ:VOR) to a strong sell rating in a research note published on Saturday.

Vor Biopharma Stock Up 19.1%

Shares of NASDAQ VOR opened at $1.06 on Friday.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.